Pharmaceuticals

Vutrisiran Market Outlook: Growth and Forecast Highlights 2030

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the vutrisiran market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Vutrisiran Market expected to reach by 2030?

The vutrisiran market size has experienced rapid expansion in recent years. It is projected to increase from $0.67 billion in 2025 to $0.75 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historic period is primarily due to breakthrough siRNA approvals, unmet needs in hATTR amyloidosis, limitations of liver transplant options, the expansion of orphan drug policies, and improved genetic diagnosis.

The vutrisiran market is projected to experience substantial expansion over the coming years, reaching a valuation of $1.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.0%. This anticipated growth stems from factors such as increasing awareness of rare diseases, a burgeoning RNA therapeutics pipeline, the greater uptake of long-acting treatment options, enhanced genetic screening, and the proliferation of specialty care facilities. Key developments influencing the market during this period encompass the wider acceptance of RNA interference therapies, a heightened emphasis on rare genetic disorders, the introduction of longer-interval dosing regimens, an escalating demand for targeted amyloidosis treatments, and the broader utilization of subcutaneous RNA medications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

What Drivers Are Driving Adoption Within The Vutrisiran Market?

The escalating investment in research and development is poised to stimulate the growth of the vutrisiran market moving forward. Research and development encompasses the systematic investigation and experimentation aimed at innovating and enhancing products, services, or processes. This increased investment in R&D is driven by various factors, including government initiatives and funding, expanding healthcare and pharmaceutical requirements, and sustainability and environmental concerns. Pharmaceutical companies leverage R&D funding to execute clinical trials, which are vital for demonstrating a drug’s long-term benefits and safety, thereby facilitating broader regulatory approvals. Concurrently, progress in RNA interference (RNAi) technology enhances drug precision, which helps reduce side effects and increases patient adoption. For example, data from the Office for National Statistics in April 2025 indicated that the UK government’s net expenditure on R&D reached approximately US $22.9 billion (£17.4 billion) in 2023, a notable increase from about US $20.0 billion (£16.1 billion) in 2022. Thus, the growing investment in research and development is a primary driver for the expansion of the vutrisiran market.

How Is The Vutrisiran Market Organized Into Various Segments?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics

2) By Route Of Administration: Injectable, Subcutaneous

3) By Patient Demographics: Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies

2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics

3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

How Are New Market Trends Shaping The Landscape Of The Vutrisiran Market?

Major companies in the vutrisiran market are broadening its application into cardiomyopathy through regulatory approvals, such as supplemental indications for ATTR CM, aiming to enlarge the patient population and maximize long-term value. A supplemental new drug application (sNDA) is a regulatory submission that extends an already approved drug’s use to new indications. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotech company, secured FDA approval for AMVUTTRA (vutrisiran) for adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), establishing it as the first RNAi therapeutic approved for both polyneuropathy and cardiomyopathy forms of the disease. Thus, this expansion into cardiomyopathy is a key trend driving growth in the vutrisiran market by increasing its clinical reach and improving patient access.

Who Are The Major Companies Operating In The Vutrisiran Market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Vutrisiran Market?

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Vutrisiran Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21320&type=smp

Browse Through More Reports Similar to the Global Vutrisiran Market 2026, By The Business Research Company

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795